secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001493152-24-043757
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem secures voting agreements for Aditxt merger; Aditxt completes $2.28M preferred investment
--------------------------------------------------------------------------------

- Evofem signed voting agreements with Series E-1 stockholders and convertible noteholders to vote in favor of merger with Aditxt subsidiary Adifem.
- Aditxt completed $2.28M final preferred investment (Series F-1), meeting $5M total commitment under A&R Merger Agreement since May 2024.
- Closing conditions require majority stockholder vote and Aditxt raising ~$17M, including ~$15.2M to satisfy Evofem's senior secured noteholder.
- If Aditxt fails to secure funds, senior secured noteholder expected to block closing; no assurance conditions will be met.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224043757/0001493152-24-043757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224043757/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-043757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer